160 related articles for article (PubMed ID: 25087901)
1. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
[No Abstract] [Full Text] [Related]
2. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
3. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
[No Abstract] [Full Text] [Related]
4. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
5. Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Blumenthal GM; Luo L; He K; Fran I; Lemery S; Pazdur R
Oncologist; 2016 Aug; 21(8):974-80. PubMed ID: 27328934
[TBL] [Abstract][Full Text] [Related]
6. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
[TBL] [Abstract][Full Text] [Related]
7. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
8. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
9. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
11. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
Toffart AC; Sakhri L; Moro-Sibilot D
Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
[TBL] [Abstract][Full Text] [Related]
12. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
Guisier F; Piton N; Salaun M; Thiberville L
Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
[No Abstract] [Full Text] [Related]
13. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
14. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
15. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
16. A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
Viola P; Maurya M; Croud J; Gazdova J; Suleman N; Lim E; Newsom-Davis T; Plowman N; Rice A; Montero MA; Gonzalez de Castro D; Popat S; Nicholson AG
J Thorac Oncol; 2016 Jul; 11(7):1029-39. PubMed ID: 27179848
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.
Tamai K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Katakami N; Tomii K
Respir Investig; 2013 Mar; 51(1):46-8. PubMed ID: 23561259
[TBL] [Abstract][Full Text] [Related]
18. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
19. [ROS-1 rearranged bronchopulmonary adenocarcinoma revealed by a pulmonary miliary].
Brindel A; Huet D; Vaillant P; Vignaud JM; Tiotiu A
Bull Cancer; 2018 Jun; 105(6):549-551. PubMed ID: 29706357
[No Abstract] [Full Text] [Related]
20. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Awad MM; Katayama R; McTigue M; Liu W; Deng YL; Brooun A; Friboulet L; Huang D; Falk MD; Timofeevski S; Wilner KD; Lockerman EL; Khan TM; Mahmood S; Gainor JF; Digumarthy SR; Stone JR; Mino-Kenudson M; Christensen JG; Iafrate AJ; Engelman JA; Shaw AT
N Engl J Med; 2013 Jun; 368(25):2395-401. PubMed ID: 23724914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]